Ignite Creation Date:
2024-05-06 @ 4:10 PM
Last Modification Date:
2024-10-26 @ 2:05 PM
Study NCT ID:
NCT04890509
Status:
COMPLETED
Last Update Posted:
2021-10-14
First Post:
2021-05-17
Brief Title:
A Study of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
Sponsor:
BerGenBio ASA
Organization:
BerGenBio ASA
Study Overview
Official Title:
A Multicentre Phase 2 Randomised Study to Assess the Efficacy and Safety of Bemcentinib for the Treatment of COVID-19 in Hospitalised Patients
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of the study is to evaluate the efficacy of bemcentinib as an add-on therapies to standard of care SoC in participants hospitalized with coronavirus disease 2019 COVID-19
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None